{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T18:43:33Z","timestamp":1773081813460,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:00:00Z","timestamp":1671062400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2023]]},"DOI":"10.1016\/j.ctarc.2022.100674","type":"journal-article","created":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T12:04:20Z","timestamp":1671192260000},"page":"100674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment"],"prefix":"10.1016","volume":"34","author":[{"given":"Eug\u00e9nie","family":"Rigault","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Lacas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Glehen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Dupont-Bierre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosine","family":"Guimbaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Malka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val\u00e9rie","family":"Boige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alina","family":"Fuerea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Pierre","family":"Pignon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8649-7449","authenticated-orcid":false,"given":"Michel","family":"Ducreux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2022.100674_bib0001","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12885-017-3925-x","article-title":"Colorectal cancer liver metastases - a population-based study on incidence, management and survival","volume":"18","author":"Engstrand","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctarc.2022.100674_bib0002","first-page":"31","article-title":"Intra-arterial infusion of anticancer drugs: theoretic aspects of drug delivery and review of responses","volume":"64","author":"Chen","year":"1980","journal-title":"Cancer Treat Rep."},{"key":"10.1016\/j.ctarc.2022.100674_bib0003","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2022.100674_bib0004","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1001\/jama.2017.7105","article-title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial","volume":"317","author":"Venook","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.ctarc.2022.100674_bib0005","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(94)90750-1","article-title":"Quality of life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases","volume":"344","author":"Allen Mersh","year":"1994","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2022.100674_bib0006","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1200\/JCO.1992.10.7.1112","article-title":"Hepatic arterial infusion of floxuridine in patients with liver metastases from colorectal carcinoma: long-term results of a prospective randomized trial [see comments]","volume":"10","author":"Rougier","year":"1992","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100674_bib0007","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S0140-6736(03)12388-4","article-title":"Intrahepatic arterial versus intravenous fluorouracil and folinic acid for colorectal cancer liver metastases: a multicentre randomised trial","volume":"361","author":"Kerr","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2022.100674_bib0008","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1093\/jnci\/88.5.252","article-title":"Reappraisal of hepatic arterial infusion in the treatment of nonresectable liver metastases from colorectal cancer. Meta- Analysis Group in Cancer [see comments]","volume":"88","year":"1996","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ctarc.2022.100674_bib0009","doi-asserted-by":"crossref","first-page":"4881","DOI":"10.1200\/JCO.2005.05.120","article-title":"Hepatic arterial oxaliplatin infusion plus intravenous chemotherapy in colorectal cancer with inoperable hepatic metastases: a trial of the gastrointestinal group of the Federation Nationale des Centres de Lutte Contre le Cancer","volume":"23","author":"Ducreux","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100674_bib0010","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1245\/s10434-007-9581-7","article-title":"Hepatic arterial infusion of oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure","volume":"15","author":"Boige","year":"2008","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.ctarc.2022.100674_bib0011","doi-asserted-by":"crossref","first-page":"3964","DOI":"10.1093\/emboj\/18.14.3964","article-title":"VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells","volume":"18","author":"Asahara","year":"1999","journal-title":"EMBO J."},{"key":"10.1016\/j.ctarc.2022.100674_bib0012","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2022.100674_bib0013","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100674_bib0014","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.ejca.2012.12.011","volume":"49","author":"Ducreux","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2022.100674_bib0015","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","article-title":"Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200","volume":"25","author":"Giantonio","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100674_bib0016","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(12)70477-1","article-title":"Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial","volume":"14","author":"Bennouna","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2022.100674_bib0017","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1093\/annonc\/mdt231","article-title":"Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings","volume":"24","author":"Kubicka","year":"2013","journal-title":"Ann. Oncol."},{"issue":"Suppl 1","key":"10.1016\/j.ctarc.2022.100674_bib0018","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1016\/j.jviscsurg.2013.12.004","article-title":"Surgical or percutaneous hepatic artery cannulation for chemotherapy","volume":"151","author":"De Baere","year":"2014","journal-title":"J. Visc. Surg."},{"key":"10.1016\/j.ctarc.2022.100674_bib0019","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.ejca.2013.09.013","article-title":"Aflibercept versus placebo in combination with fluorouracil, leucovorin and irinotecan in the treatment of previously treated metastatic colorectal cancer: prespecified subgroup analyses from the VELOUR trial","volume":"50","author":"Tabernero","year":"2014","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.ctarc.2022.100674_bib0020","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S1470-2045(15)70127-0","article-title":"Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised","volume":"16","author":"Tabernero","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ctarc.2022.100674_bib0021","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1200\/JCO.1994.12.11.2288","article-title":"Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma","volume":"12","author":"Kemeny","year":"1994","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2022.100674_bib0022","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1093\/annonc\/mdv548","article-title":"Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV","volume":"27","author":"Levi","year":"2016","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ctarc.2022.100674_bib0023","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10585-011-9432-6","article-title":"Hepatic arterial infusion of bevacizumab in combination with oxaliplatin reduces tumor growth in a rat model of colorectal liver metastases","volume":"29","author":"Sperling","year":"2012","journal-title":"Clin. Exp. Metastasis"}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222001654?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294222001654?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:34:00Z","timestamp":1762842840000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294222001654"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023]]},"references-count":23,"alternative-id":["S2468294222001654"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100674","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2023]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intra-arterial hepatic bevacizumab and systemic chemotherapy in hepatic metastasis of colorectal cancer: A phase II multicentric trial in second-line treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2022.100674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100674"}}